SurModics Inc (SRDX)

[north40000]

For a different slant on this statement:

"We see this kind of reluctance also in the hepatitis and cancer arenas, where a cocktail of experimental drugs may be a compelling choice from a scientific standpoint, but no one is willing to undertake the clinical trials and each company instead pushes its own drug in combination with already-approved therapies."

readers might check slides 6 and 13 on the MEDX presentation
at Bear Stearns this past Monday:


http://cc.talkpoint.com/BEAR002/091106a_cy/linkdefault.asp?entity=medarex

Slide 6 shows 2 unapproved drugs----MDX-010 and MDX-1379---
in combination for melanoma, with complete responses now
extending past 40 months in some patients. SPA, I believe.

Slide 13 shows 2 unapproved drugs---MDX-066 + MDX1388---
in Phase II trials initiated in 09/06 against toxins A and
B of C. Difficile.